Targeting SLC35E3 for Bladder Cancer Treatment (G55508)

Target Name: SLC35E3

NCBI ID: G55508

SLC35E3

Targeting SLC35E3 for Bladder Cancer Treatment

Bladder cancer is a common type of cancer that affects the bladder, a small pouch that holds urine in the urinary system. It is estimated that over 50% of all bladder cancers are high-risk, meaning that they have the potential to spread quickly and are often treated with aggressive chemotherapy. Despite advances in cancer treatment, the survival rate for bladder cancer remains relatively low.

One potential solution to this problem is the use of drugs that target specific genes associated with bladder cancer. One such gene is SLC35E3, also known as Bladder cancer-overexpressed gene 1 protein (BCAP).

SLC35E3 is a protein that is expressed in high levels in bladder cancer cells. It is a member of the superfamily of transmembrane protein (SMT) genes, which are involved in a wide range of cellular processes, including signaling and transport. SLC35E3 is specifically involved in the regulation of cell growth and differentiation, as well as cell survival.

Studies have suggested that SLC35E3 may be a potential drug target for bladder cancer. By targeting this gene, drugs could potentially inhibit its activity and reduce the growth and spread of cancer cells. This could lead to improved treatment outcomes and increased survival rates for people with bladder cancer.

One way that SLC35E3 may be used to treat bladder cancer is through the use of inhibitors, also known as small molecules or drugs. These inhibitors would work by binding to the SLC35E3 protein and preventing it from doing its job. This could lead to a reduction in the amount of SLC35E3 protein that is produced in cancer cells, which could in turn inhibit their growth and spread.

Another potential approach to treating bladder cancer with SLC35E3 is through the use of monoclonal antibodies. These antibodies are laboratory-made versions of immune system proteins that are designed to recognize and attack specific targets in cancer cells. By using SLC35E3 as a target for the antibodies, they can specifically destroy cancer cells that contain this gene.

In addition to its potential as a drug target, SLC35E3 is also being studied as a potential biomarker for bladder cancer. This means that researchers are using it to track the progress of the disease and to identify new treatments. By measuring the levels of SLC35E3 in cancer cells and using it as a marker, researchers can potentially identify which patients are most likely to respond to a given treatment and which will be most effective.

Overall, SLC35E3 is a promising gene that may be used to treat bladder cancer. By targeting its activity, researchers can potentially inhibit the growth and spread of cancer cells and improve treatment outcomes for people with this disease. Further research is needed to fully understand the potential of SLC35E3 as a drug target and biomarker for bladder cancer.

Protein Name: Solute Carrier Family 35 Member E3

Functions: Putative transporter

The "SLC35E3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35E3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets